NASDAQ : TTRX
Turn Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 319.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 310.69M |
| Enterprise Value | 306.52M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 29.79M |
| Shares Outstanding | 29.79M |
| Shares Change (YoY) | +7.08% |
| Shares Change (QoQ) | +1.06% |
| Owned by Insiders (%) | 57.82% |
| Owned by Institutions (%) | 3.92% |
| Float | 11.12M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 452.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.19 |
| Quick Ratio | 1.17 |
| Debt / Equity | 8.91 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -38.36 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -686.28% |
| Return on Assets (ROA) | -50.27% |
| Return on Invested Capital (ROIC) | -123.26% |
| Return on Capital Employed (ROCE) | -104.47% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.22M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | +98.67% |
| 50-Day Moving Average | 11.73 |
| 200-Day Moving Average | 7.00 |
| Relative Strength Index (RSI) | 43.37 |
| Average Volume (20 Days) | 94,729 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 431,200 |
| Short Previous Month | 268,757 |
| Short % of Shares Out | 1.45% |
| Short % of Float | 3.88% |
| Short Ratio (days to cover) | 2.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -1.61M |
| Operating Income | -8.56M |
| Pretax Income | -8.45M |
| Net Income | -8.45M |
| EBITDA | -8.51M |
| EBIT | -8.56M |
| Earnings Per Share (EPS) | -$0.29 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 10.29M |
| Total Debt | 6.12M |
| Net Cash | 4.17M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 686,888 |
| Book Value Per Share | 0.02 |
| Working Capital | 1.66M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.32M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 56,816 |
| Net Borrowing | 6.72M |
| Free Cash Flow | -4.32M |
| FCF Per Share | -$0.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.08% |
| Shareholder Yield | -7.08% |
| Earnings Yield | -2.80% |
| FCF Yield | -1.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.00 |
| Price Target Difference | 139.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |